BX471 hydrochloride

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BX471 hydrochloride

CAS No. : 288262-96-4

MCE 国际站：BX471 hydrochloride

产品活性：BX471 hydrochloride (ZK-811752 hydrochloride) 是以一种有效的，选择性的，非肽段的 CCR1 拮抗剂，抑制人 CCR1 活性，K_i 值为 1 nM，对其选择性是对 CCR2，CCR5 和 CXCR4 的 250 倍。

研究领域：GPCR/G Protein  |  Immunology/Inflammation

作用靶点：CCR

In Vitro: BX471 is a potent functional antagonist based on its ability to inhibit a number of CCR1-mediated effects including Ca²⁺ mobilization, increase in extracellular acidification rate, CD11b expression, and leukocyte migration. BX471 demonstrats a greater than 10,000-fold selectivity for CCR1 compared with 28 G-protein-coupled receptors. BX471 is also able to displace ¹²⁵I-MIP-1α/CCL3 binding to mouse CCR1 in a concentration-dependent manner with a K_i of 215±46 nM. Increasing concentrations of BX471 inhibits the Ca²⁺ transients induced by MIP-1α/CCL3 in both human and mouse CCR1 with IC₅₀ of 5.8±1 nM and 198±7 nM, respectively. BX471 (0.1-10 μM) shows a dose-dependent inhibition of RANTES-mediated and shear-resistant adhesion on IL-1β-activated microvascular endothelium in shear flow in isolated blood monocytes. BX471 also inhibits the RANTES-mediated adhesion of T lymphocytes to activated endothelium.

In Vivo: BX471 (4 mg/kg, p.o. or i.v.) is orally active with a bioavailability of 60% in dogs. Furthermore, BX471 effectively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis. BX471 (20 mg/kg, s.c.) reaches peak plasma levels of 9 μM by around 30 minutes, and this rapidly declines to approximately 0.4 μM after 2 hours. From 4 to 8 hours the drug plasma levels drops to 0.1 μM or lower. Mice treated with 20 mg/kg of BX471 for 10 days shows a reduction of interstitial CD45 positive leukocytes of approximately 55%. BX471 has a borderline significant effect on the number of CCR5-positive CD8 cells in the peripheral blood. BX471 reduces the amount of FSP1-positive cells by 65% in UUO kidneys as compared with vehicle control. Pretreatment witih BX471 reduces macrophage and neutrophil accumulation in kidney after ischemia-reperfusion injury.

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Endocrinology Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Chemokine Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Cytokine Inhibitors Library  |  Pirfenidone  |  Maraviroc  |  RS 504393  |  Bindarit  |  INCB3344  |  BX471  |  PF-4136309  |  RS102895 hydrochloride  |  Cenicriviroc  |  TAK-779  |  CCR6 inhibitor 1  |  Zelnecirnon  |  CCR6 antagonist 1  |  AZ084  |  ZK756326 dihydrochloride  |  AZD2098  |  GW 766994  |  R243  |  7,4'-Dihydroxyflavone  |  BMS-813160  |  CCR7 Ligand 1  |  MK-0812 Succinate  |  K777  |  Vercirnon  |  DAPTA  |  Tivumecirnon  |  C-021  |  CCR2 antagonist 4 hydrochloride  |  INCB 3284

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds